Effects of selective serotonin re-uptake inhibition on MOrbidity, mOrtality and mood in Depressed Heart Failure patients.

Trial Profile

Effects of selective serotonin re-uptake inhibition on MOrbidity, mOrtality and mood in Depressed Heart Failure patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms MOOD-HF
  • Most Recent Events

    • 28 Jun 2016 Primary endpoint has not been met. (All-cause death or hospitalization), as per results published in the JAMA: the Journal of the American Medical Association.
    • 28 Jun 2016 Results published in the JAMA: the Journal of the American Medical Association
    • 16 Nov 2011 Status changed from completed to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top